Accessibility Menu
Inhibrx Biosciences Stock Quote

Inhibrx Biosciences (NASDAQ: INBX)

$31.05
(-1.5%)
-0.47
Price as of October 23, 2025, 2:42 p.m. ET

KEY DATA POINTS

Current Price
$31.05
Daily Change
(-1.5%) $0.47
Day's Range
$30.8 - $36.31
Previous Close
$31.52
Open
$35.01
Beta
0.81
Volume
419,941
Average Volume
128,582
Market Cap
456.6M
Market Cap / Employee
$31.52M
52wk Range
$10.81 - $39.27
Revenue
-
Gross Margin
-0.99%
Dividend Yield
N/A
EPS
-$10.99
CAPs Rating
-
Industry
Biotechnology

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Inhibrx Biosciences Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
INBX+99.49%N/AN/A+126%
S&P+14.5%+93.32%+14.09%+27%

Inhibrx Biosciences Company Info

Inhibrx Biosciences, Inc. operates as an American clinical-stage biotechnology company for biologic therapeutic candidates. The private company is based in DE.

News & Analysis

Financial Health

General

Q2 2025YOY Change
Revenue$1.30M1200.0%
Gross Profit$0.64M270.1%
Gross Margin49.08%424.1%
Market Cap$206.57M0.7%
Market Cap / Employee$1.28M0.0%
Employees1610.0%
Net Income-$28.65M-101.5%
EBITDA-$26.73M83.3%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$186.57M-17.8%
Accounts Receivable$0.24M-45.5%
Inventory00.0%

Liabilities

Q2 2025YOY Change
Long Term Debt$104.62M0.0%
Short Term Debt$2.17M-0.1%

Ratios

Q2 2025YOY Change
Return On Assets-69.58%0.0%
Return On Invested Capital351.55%426.8%

Cash Flow

Q2 2025YOY Change
Free Cash Flow-$29.95M48.9%
Operating Free Cash Flow-$29.95M47.8%

Valuation

MetricQ4 2024Q1 2025YoY Change
Price to Earnings0.130.12-
Price to Book1.031.251.522.19-87.66%
Price to Sales1114.641081.99157.66-
Price to Tangible Book Value1.031.251.522.19-87.66%
Enterprise Value to EBITDA-0.70-1.59-2.52-5.27-4424.13%
Return on Equity3250.6%-113.7%-
Total Debt$1.84M$8.05M$106.53M$106.79M4818.89%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.